Codagenix Collaborates with Serum Institute of India to Co-Develop a Live-Attenuated Vaccine Against Coronavirus (COVID-19)

 Codagenix Collaborates with Serum Institute of India to Co-Develop a Live-Attenuated Vaccine Against Coronavirus (COVID-19)

Codagenix Collaborates with Serum Institute of India to Co-Develop a Live-Attenuated Vaccine Against Coronavirus (COVID-19)

Shots:

  • Codagenix will utilize its deoptimization technology for viral deoptimization, designed several nCoV vaccine candidate genomes, will grow and conduct in-vivo tests of vaccine viruses prior to testing in clinical studies
  • The Serum Institute of India will scale up the manufacturing of vaccines to ensure its availability to meet the public needs. The companies are pursuing an accelerated development pathway to speed up the availability of vaccine
  • The focus of the collaboration is to develop a live-attenuated vaccine, inducing an immune response to multiple antigens of the virus and enables scale for mass production

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Codagenix

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post